flutiform offers rapid bronchodilation

flutiform delivers significantly faster bronchodilation than fluticasone propionate/salmeterol pMDI as maintenance therapy.1* Fast-acting maintenance agents may improve adherence.2-4

*flutiform is not indicated for use as a reliever medication.

12-week, open label, randomised study in patients ≥18 years. Post-hoc analysis of a secondary endpoint. Primary endpoint: pre-dose FEV1 at week 12; *p≤0.05 at these points.1 FEV1: forced expiratory volume in 1 second; b.i.d: twice daily; FP: fluticasone propionate.

1. Aalbers R et al. Adv Ther. 2012; 29(11): 958–969. 2. Partridge MR et al. BMC Pulm Med 2006; 6: 13. 3. Murphy KR and Bender BG. J Asthma Allergy 2009; 2: 63–72. 4. Hauber AB et al. Allergy Asthma Proc 2009; 30: 139–147.

You are now leaving flutiform.com and moving to an external website independently operated and not managed by Mundipharma International Ltd. Mundipharma International Ltd assumes no responsibility for the site or its content.

If you do not wish to leave this site, click Cancel or click OK to continue.

OK Cancel